Prostacyclin analogues such as epoprostenol (Flolan®) are commonly used in the treatment of pulmonary arterial hypertension (PAH). However, their complex administration and significant cost may limit the access that patients with PAH have to palliative and hospice care. We herein report our experience using epoprostenol in a dedicated palliative care unit and present our inpatient protocol for the drug's administration.
Get full access to this article
View all access options for this article.
References
1.
ParamothayanNS, LassersonTJ, WellsAU, WaltersEH. Prostacyclin for pulmonary hypertension in adults. Cochrane Database Syst Rev, 2005; 2:CD002994.
2.
ShafazandS, GoldsteinMK, DoyleRL, HlatkyMA, GouldMK. Health-related quality of life in patients with pulmonary arterial hypertension. Chest, 2004; 126:1452–1459.
3.
GrinnanDC, ShipleyJ, SwetzK, PinsonJ, FairmanRP. The Health Care Initiative for Improving End of Life in Pulmonary Hypertension (CARING)2010 American Thoracic Society International Conference, New Orleans, LA, May 17, 2010.
BarstRJ, RubinLJ, LongWA, McGoonMD, RichS, BadeschDB, GrovesBM, TapsonVF, BourgeRC, BrundageBH, KoernerSK, LanglebenD, KellerCA, MuraliS, UretskyBF, ClaytonCM, JöbsisMM, BlackburnSD, ShortinoD, CrowJW. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med, 1996; 334:296–302.
6.
FalkJA, PhillipKJ, SchwarzER. The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. Vasc Health Risk Manage, 2010; 6:273–280.
